These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39171280)

  • 21. Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during Omicron BA.1/BA.2 and BA.5-predominant periods in Japan.
    Tomioka K; Uno K; Yamada M
    Environ Health Prev Med; 2023; 28():35. PubMed ID: 37286499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of Inactivated COVID-19 Vaccines against COVID-19 Caused by the SARS-CoV-2 Delta and Omicron Variants: A Retrospective Cohort Study.
    Hua Q; Zheng D; Yu B; Tan X; Chen Q; Wang L; Zhang J; Liu Y; Weng H; Cai Y; Xu X; Feng B; Zheng G; Ding B; Guo J; Zhang Z
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different effects of vaccine on VST in critical and non-critical COVID-19 patients: A retrospective study of 363 cases.
    Ying-Hao P; Rui-Han L; Hai-Dong Z; Qiu-Hua C; Yuan-Yuan G; Yu-Shan Y; Hai-Qi Z; Hua J
    Heliyon; 2023 May; 9(5):e16017. PubMed ID: 37153418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave.
    Lu G; Zhang Y; Zhang H; Ai J; He L; Yuan X; Bao S; Chen X; Wang H; Cai J; Wang S; Zhang W; Xu J
    Emerg Microbes Infect; 2022 Dec; 11(1):2045-2054. PubMed ID: 35924388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.
    He X; Zeng B; Wang Y; Pang Y; Zhang M; Hu T; Liang Y; Kang M; Tang S
    Front Immunol; 2023; 14():1257360. PubMed ID: 37915583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical factors associated with viral shedding time of SARS-CoV-2 Omicron variant in Japan.
    Akata K; Yamasaki K; Kohrogi R; Kawakami Y; Furuya Y; Eto K; Honda M; Suzuki K; Yatera K
    J Infect Chemother; 2024 Feb; 30(2):172-175. PubMed ID: 37820950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
    Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
    Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China.
    Wang K; Guo Z; Zeng T; Sun S; Lu Y; Wang J; Li S; Luan Z; Li H; Zhang J; Wang Y; Lu Y; Zhao S
    JAMA Netw Open; 2023 Mar; 6(3):e235755. PubMed ID: 36995713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with negative conversion of viral RNA in hospitalized children infected with SARS-CoV-2 Omicron variant in Shanghai, China: a retrospective analysis.
    Yang Y; You Y; Liu Y; Geng L; Huang L; Zhou H; Piao X; Liu X; Wu M; Wang Y; Zhou L; Wang P; Shen S; Hu M; Han Z; Xue Z
    BMC Infect Dis; 2023 Apr; 23(1):264. PubMed ID: 37101288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of clinical characteristics and vaccines with risk of persistently viral clearance in patients infected with SARS-CoV-2 Omicron variant in Shanghai, China.
    Zhang W; Wu H; Guo Q; Xu X; Pu Y; Chen C; Cao M; Sun D; Lu W; Yi H; Zhou S; Fang B
    Heliyon; 2024 Jan; 10(1):e23256. PubMed ID: 38192786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
    Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
    JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding clinical characteristics influencing adverse outcomes of Omicron infection: a retrospective study with propensity score matching from a Fangcang hospital.
    Geng Y; Nie Q; Liu F; Pei Y; Chen Q; Zhang H; Zhou H; Zhou J; Jiang H; Xu J
    Front Cell Infect Microbiol; 2023; 13():1115089. PubMed ID: 37228665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants.
    Wu D; Ye Y; Tang L; Wang AB; Zhang R; Qian ZH; Wang FZ; Zheng H; Huang C; Lv XY; Wang HF; Zhang YY; Pan JJ; Li YF; Lu MX; Wang CS; Ma YT; An ZJ; Rodewald LE; Yin ZD; Wang XY; Wu ZY; Shao YM
    Emerg Microbes Infect; 2022 Dec; 11(1):1950-1958. PubMed ID: 35850623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China.
    Liao Y; Su J; Zhao J; Qin Z; Zhang Z; Gao W; Wan J; Liao Y; Zou X; He X
    Front Immunol; 2024; 15():1359380. PubMed ID: 38881892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study.
    Zhang D; Zhong J; Xiong H; Li Y; Guo T; Peng B; Fang C; Kang Y; Tan J; Ma Y
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
    J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.